Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis;Intérêt de l'association ceftazidime et aztréonam dans les exacerbations de mucoviscidose à Pseudomonas aeruginosa multirésistant

Revue des Maladies Respiratoires

Volumn 27, Issue 5, 2010, Pages 449-456

  Prevotat A ^a   Leroy, S ^a   Perez, T ^a   Wallet, F ^a   Wallaert, B ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Aztreonam; Ceftazidime; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

AZTREONAM; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TOBRAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EVALUATION; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FIBROSIS; MALE; NONHUMAN; OXYGEN SATURATION; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; AZTREONAM; CEFTAZIDIME; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77955014002     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmr.2010.03.015     Document Type: Article

References (19)

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951
2. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681-689
3. Aubron C, Rapp C, Parienti JJ, Patey O. An update on inhaled antibiotherapy in Pseudomonas aeruginosa respiratory tract infections. Med et Mal Inf 2002;32:460-467
4. Doring G, Conway SP, Heiman Jr. HG, Hodson ME, Hoiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767
5. Bremont F. Criteres cliniques de l'infection a Staphylococcus aureus et au Pseudomonas aeruginosa. Rev Mal Respir 2003;20(3):S57-61.
6. Bosso JA, Saxon BA, Matsen JM. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrob Agents Chemother 1990;34:487-488
7. Lister PD, Sanders WE, sanders C. Cefepime-aztreonam: a unique double 0-lactam combination for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998;42(7):1610-1619
8. OieS, Uematsu T, Sawa A, Mizuno H, TomitaM, IshidaS, et al. In vitro effect of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2003;52:911-914
9. Cystic Fibrosis, Foundation. Microbiology and infectious disease in cystic fibrosis. Consensus conference, concepts in care, Consensus Conference, V. Bethesda, MD: Cystic Fibrosis Foundation; 1994. p. 1-26.
10. Marguet C. Management of patients (children and adults) with cystic fibrosis. Arch Pediatr 2003;3:381s.
11. Kuzemko J, Crawford C. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989;2:385.
12. Vinks AA, Brimicombe RW, Heijerman HG, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokine- tics. J Antimicrob Chemother 1997;40:125-133
13. David TJ, Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989;1:1454.
14. De Boeck K, Breysem L. Treatment of Pseudomonas xruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime. J Antimicrob Chemother 1998;41:407-409
15. Bosso JA, Black PG, Matsen JM. Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J 1987;6:393-397
16. Jensen T, Pedersen SS, Hoiby N, Koch C. Safety of aztreonam in patients with cystic fibrosis and allergy to beta-lactam antibiotics. Rev Infect Dis 1991;13:S594-7.
17. Sahl B, Bilton D, Dodd M, Abbot J, Webb K. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scand J Infect Dis 1992;24(2):215-218
18. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas xruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003;123:1495-1502
19. Mayaud C, groupe ECRIR. Pseudomonas and bronchial disease. Med Mal Inf 2007:300-304